Trial Profile
A Phase II Study of R-FND, Followed by Zevalin Radioimmunotherapy, and Subsequent Maintenance Rituximab for Advanced Stage Follicular Lymphoma With High-Risk Features
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Apr 2022
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab (Primary) ; Dexamethasone; Dexamethasone; Fludarabine; Mitoxantrone
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 15 Feb 2021 Status changed from active, no longer recruiting to completed.
- 05 Jan 2020 Planned primary completion date changed from 24 Aug 2019 to 24 Aug 2020.
- 20 May 2019 Planned End Date changed from 24 Aug 2019 to 24 Aug 2020.